Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascendis Pharma ( (ASND) ) has provided an announcement.
On April 20, 2026, Ascendis Pharma began trading its ordinary shares directly on the Nasdaq Global Select Market, replacing its prior listing of American Depositary Shares while keeping the ASND ticker, CUSIP K08588103 and ISIN DK0060606333. The shift follows an April 8, 2026 decision to mandatorily exchange each ADS for one Nasdaq-listed ordinary share, with ADS trading ending April 17 and all outstanding ADSs converted by April 20, simplifying the capital structure and aligning U.S. investors with the company’s home-market equity.
This move streamlines the company’s listing framework, potentially reducing administrative complexity associated with ADSs and offering clearer exposure to Ascendis Pharma’s ordinary equity for global investors. The transition may also enhance liquidity and comparability with European peers, signaling the company’s intent to strengthen its presence in U.S. capital markets and improve accessibility for existing and prospective shareholders.
The most recent analyst rating on (ASND) stock is a Buy with a $292.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company listed in the United States, focusing on developing and commercializing therapies using its proprietary technology platform. Its ordinary shares now trade on the Nasdaq Global Select Market under the ticker symbol ASND, targeting global healthcare and life sciences investors.
Average Trading Volume: 674,263
Technical Sentiment Signal: Buy
Current Market Cap: $14.84B
For an in-depth examination of ASND stock, go to TipRanks’ Overview page.